Mederi Therapeutics Announces Receipt of CE Mark for its Second Generation Secca(R) and Stretta(R) Systems

GREENWICH, Connecticut, November 8, 2010 - Mederi Therapeutics Inc announced today that it has received a CE Mark
authorizing the European distribution and use of Mederi's second generation
of the Stretta and Secca Systems. The Stretta System is for treatment of
gastric reflux disease, commonly known as GERD, and the Secca System is for
treatment of bowel control disorder, or BCD. These latest systems include a
streamlined user interface, significant improvements in ease of use, and are
smaller, lighter, and highly portable.

"Mederi is very pleased to offer the Stretta system for the treatment
GERD and the Secca system for treatment of BCD. Mederi has made a substantial
capital investment which has resulted in numerous improvements to these novel
technologies," stated Will Rutan, CEO and President of Mederi Therapeutics.
"The Secca and Stretta systems are ultra-minimally invasive technologies that
bridge a significant gap that exists between conservative therapies and
invasive surgical options for GERD and BCD. Numerous clinical studies have
shown Stretta and Secca to be effective therapeutic options."

The second generation Stretta and Secca devices were launched at UEGW
2010, the annual congress of the United European Gastroenterology Federation,
which was held in Barcelona, Spain, October 23-27. "It was exciting to
witness the overwhelming response to Stretta and Secca, resulting in numerous
requests to purchase Mederi products at the recent European congress. As the
only endoluminal therapies for GERD and BCD, the interest and demand for
these novel technologies is extremely high," added Rutan. Concurrent with the
EU launch activities, Mederi has engaged and trained a worldwide distribution
network to drive demand and ensure safe and proper use of Stretta and Secca.

The CE Mark and ISO 13485 certification demonstrate Mederi's steadfast
commitment to safety and quality.

Additional information is available at www.mederitherapeutics.com.

ABOUT MEDERI

Mederi Therapeutics manufactures and markets innovative medical devices
that deliver radiofrequency energy to treat disease states affecting the
human digestive system. All Mederi therapies are outpatient, minimally
invasive, and promote rapid recovery. Mederi Therapeutics is located in
Greenwich, Connecticut.

    Contact: Sheila Doyle
             Manager of Communications and Marketing
             +1-203-930-9980

Sheila Doyle, Manager of Communications and Marketing, +1-203-930-9980